Daily Stock Analysis, BSTG, Harvard Apparatus Regenerative Technology Inc , priceseries

Harvard Apparatus Regenerative Technology Inc . Daily Stock Analysis
Stock Information
Open
0.25
Close
0.27
High
0.27
Low
0.23
Previous Close
0.23
Daily Price Gain
0.03
YTD High
0.95
YTD High Date
Jan 3, 2017
YTD Low
0.22
YTD Low Date
May 22, 2017
YTD Price Change
-0.60
YTD Gain
-69.31%
52 Week High
1.59
52 Week High Date
May 24, 2016
52 Week Low
0.22
52 Week Low Date
May 22, 2017
52 Week Price Change
-1.23
52 Week Gain
-82.20%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Dec 31. 2014
3.18
Jan 14. 2015
3.65
9 Trading Days
14.68%
Link
LONG
Feb 12. 2015
2.58
Feb 23. 2015
3.08
6 Trading Days
19.38%
Link
LONG
Feb 25. 2015
3.32
Mar 12. 2015
4.04
11 Trading Days
21.71%
Link
LONG
Aug 25. 2015
0.85
Sep 11. 2015
1.15
12 Trading Days
34.78%
Link
LONG
Nov 11. 2015
0.63
Dec 4. 2015
2.24
16 Trading Days
255.27%
Link
LONG
Mar 2. 2016
1.39
Mar 18. 2016
1.68
12 Trading Days
21.13%
Link
LONG
Apr 27. 2016
1.88
May 12. 2016
2.12
11 Trading Days
13.01%
Link
Company Information
Stock Symbol
BSTG
Exchange
NasdaqCM
Company URL
http://www.harvardapparatusregen.com
Company Phone
(774) 233-7300
CEO
James J. McGorry
Headquarters
Massachusetts
Business Address
84 OCTOBER HILL ROAD, SUITE 11, HOLLISTON, MA 01746
Sector
-
Industry Category
-
Industry Group
-
CIK
0001563665
About

Harvard Apparatus Regenerative Technology, Inc., a clinical stage biotechnology company, develops and commercializes regenerated organs for human transplant.

Description

Harvard Apparatus Regenerative Technology, Inc., a clinical stage biotechnology company, develops and commercializes regenerated organs for human transplant. The company is developing the HART-Trachea, which includes a scaffold, the patient’s cells, and a bioreactor to restore the structure and/or function of a severely damaged trachea; and automated solid organ bioreactor that has the ability to seed cells on an organ scaffold and keep them sterile and healthy during the growth phase prior to transplant. Its pre-clinical stage products include human-sized synthetic scaffold prototypes for esophageal transplant. The company has a pre-clinical collaboration with Connecticut Children's Medical Center to develop a process for repairing or replacing the esophagus to treat life-threatening pediatric conditions, such as esophageal atresia. Harvard Apparatus Regenerative Technology, Inc. was founded in 2007 and is headquartered in Holliston, Massachusetts.